Agilon Health, Inc. (NYSE:AGL) Receives Average Recommendation of "Hold" from Brokerages

Key Points

• Agilon Health currently has a consensus brokerage rating of “Hold”, based on 14 analysts, with a mixed split of three sell, six hold, and five buy ratings.
• The company delivered a strong Q1 2026 earnings beat, reporting $1.80 EPS versus $1.04 expected and revenue of $1.42 billion versus $1.38 billion expected, which helped drive a sharp stock rally.
• Management also raised full-year 2026 guidance, suggesting recent operational changes may be improving the business, while several analysts adjusted targets and ratings in response to the results.

Shares of Agilon Health, Inc. (NYSE:AGL - Get Free Report) have been assigned a consensus recommendation of "Hold" from the fourteen brokerages that are covering the stock, MarketBeat reports. Three research analysts have rated the stock with a sell rating, six have given a hold rating and five have issued a buy rating on the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $37.9250.

A number of equities analysts have issued reports on the company. Wells Fargo & Company restated an "overweight" rating and set a $72.00 price target (up from $37.50) on shares of Agilon Health in a report on Friday. Wall Street Zen upgraded Agilon Health from a "sell" rating to a "hold" rating in a report on Saturday. Citigroup cut their price target on Agilon Health from $21.25 to $18.75 and set a "neutral" rating on the stock in a report on Tuesday, March 3rd. Jefferies Financial Group upgraded Agilon Health from a "hold" rating to a "buy" rating and increased their price target for the stock from $27.50 to $48.00 in a report on Thursday. Finally, JPMorgan Chase & Co. cut Agilon Health from a "neutral" rating to an "underweight" rating and set a $21.00 price target on the stock. in a report on Monday, May 4th.

Agilon Health News Roundup

Here are the key news stories impacting Agilon Health this week:

• Positive Sentiment: Agilon Health reported Q1 2026 earnings of $1.80 per share, well above Wall Street estimates, and revenue also topped expectations, helping fuel a major rally in the stock. Agilon Health Operational Initiatives Begin Showing Results
• Positive Sentiment: The company raised its full-year 2026 guidance, with revenue outlook above consensus, signaling that recent operational initiatives may be starting to pay off. Agilon Health Operational Initiatives Begin Showing Results
• Positive Sentiment: Several coverage pieces highlighted the strong quarter and the stock’s big move, reinforcing investor optimism around the turnaround story. agilon health NYSE: AGL Reports Strong Q1 CY2026, Stock Jumps 27.9%
• Neutral Sentiment: Jefferies upgraded Agilon Health, adding to the positive sentiment, though another firm, Robert W. Baird, raised its price target while keeping a neutral view on the stock. Jefferies upgrades Agilon Health (AGL)
• Neutral Sentiment: Recent earnings-call transcripts and analysis focused on the company’s performance details and management commentary, but did not add a materially new catalyst beyond the earnings beat and guidance increase. Agilon Health, Inc. NYSE: AGL Q1 2026 Earnings Call Transcript
• Negative Sentiment: While not a fresh negative catalyst, prior reporting noted Agilon had been under pressure in 2025 due to weak financial performance and a suspended guidance outlook, which helps explain why the recent rebound is being viewed as a turnaround. Agilon Health Is Up 115% After Earnings. Why the Stock Is Having Its Best Day Ever.

Institutional Trading of Agilon Health

Hedge funds have recently bought and sold shares of the business. Wealthcare Advisory Partners LLC acquired a new stake in Agilon Health in the 3rd quarter valued at $26,000. CIBC Bancorp USA Inc. acquired a new stake in shares of Agilon Health in the 3rd quarter worth about $34,000. Pilgrim Partners Asia Pte Ltd acquired a new stake in shares of Agilon Health in the 3rd quarter worth about $37,000. Tower Research Capital LLC TRC raised its holdings in shares of Agilon Health by 214.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 37,079 shares of the company's stock worth $85,000 after acquiring an additional 25,270 shares during the last quarter. Finally, Independent Advisor Alliance acquired a new stake in shares of Agilon Health in the 3rd quarter worth about $39,000.

Agilon Health Price Performance

Agilon Health stock opened at $53.86 on Friday. The stock has a market capitalization of $897.22 million, a price-to-earnings ratio of -2.50 and a beta of 2.29. Agilon Health has a 52-week low of $7.48 and a 52-week high of $82.00. The stock's 50 day moving average price is $18.83 and its two-hundred day moving average price is $18.25. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.02 and a current ratio of 1.04.

Agilon Health (NYSE:AGL - Get Free Report) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $1.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.04 by $0.76. The firm had revenue of $1.42 billion for the quarter, compared to analysts' expectations of $1.38 billion. Agilon Health had a negative return on equity of 146.03% and a negative net margin of 6.09%. On average, equities analysts predict that Agilon Health will post -6.36 earnings per share for the current year.

Agilon Health Company Profile

Agilon Health NYSE: AGL is a healthcare company that partners with independent primary care physicians to deliver value-based care for Medicare beneficiaries. Through risk-sharing arrangements, Agilon assumes financial responsibility for patient populations, enabling physicians to focus on preventive and proactive health management. The company provides the administrative, clinical and operational infrastructure needed to support comprehensive care delivery.

Agilon’s platform encompasses data analytics, care management, patient engagement tools and population health programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.